CIK 0002035832 · <br>Emerging growth company
Aktis Oncology, Inc.
Sign in to watch- Ticker
- AKTS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 852584233
- Phone
- 978-237-4380
- Business address
- 17 DRYDOCK AVENUE, SUITE #17-401, BOSTON, MA, 02210
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $258,621
- in 1 filing, $259K under 10b5-1 plans
Net −$258,621. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-23 | Czibere Akos Chief Medical Officer | Option exercise 10b5-1 | +12,500 | $4.95 | $62K | 12,500 |
| 2026-09-23 | Czibere Akos Chief Medical Officer | Sale 10b5-1 | −5,099 | $20.19 | $103K | 7,401 |
| 2026-09-23 | Czibere Akos Chief Medical Officer | Sale 10b5-1 | −7,401 | $21.03 | $156K | 0 |
| 2026-09-23 | Czibere Akos Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −12,500 | 208,718 | ||
| 2026-07-20 | Herrmann Ken Director | Option exercise | +3,506 | $0.08 | $280 | 3,506 |
| 2026-07-20 | Herrmann Ken Director | Option exercise | +1,350 | $1.91 | $3K | 4,856 |
| 2026-07-20 | Herrmann Ken Director | Sale | −3,506 | $24.56 | $86K | 1,350 |
| 2026-07-20 | Herrmann Ken Director | Sale | −1,350 | $24.56 | $33K | 0 |
| 2026-07-20 | Herrmann Ken Director | Option exercise · Stock Option (Right to Buy) | −3,506 | 0 | ||
| 2026-07-20 | Herrmann Ken Director | Option exercise · Stock Option (Right to Buy) | −1,350 | 18,364 | ||
| 2026-07-17 | Herrmann Ken Director | Option exercise | +3,065 | $0.08 | $245 | 3,065 |
| 2026-07-17 | Herrmann Ken Director | Sale | −3,065 | $25.21 | $77K | 0 |
| 2026-07-17 | Herrmann Ken Director | Option exercise · Stock Option (Right to Buy) | −3,065 | 3,506 | ||
| 2026-07-08 | Ron-Bigger Shulamit Chief Operating Officer | Option exercise | +50,000 | $3.66 | $183K | 50,000 |
| 2026-07-08 | Ron-Bigger Shulamit Chief Operating Officer | Sale | −15,800 | $27.13 | $429K | 34,200 |
| 2026-07-08 | Ron-Bigger Shulamit Chief Operating Officer | Sale | −30,000 | $27.94 | $838K | 4,200 |
| 2026-07-08 | Ron-Bigger Shulamit Chief Operating Officer | Sale | −4,200 | $28.75 | $121K | 0 |
| 2026-07-08 | Ron-Bigger Shulamit Chief Operating Officer | Option exercise · Stock Option (Right to Buy) | −50,000 | 217,888 | ||
| 2026-07-08 | Czibere Akos Chief Medical Officer | Option exercise | +50,000 | $4.95 | $248K | 50,000 |
| 2026-07-08 | Czibere Akos Chief Medical Officer | Sale | −14,800 | $27.13 | $401K | 35,200 |
Page 1 of 4 · 76 trades